Lucid Diagnostics Inc
NASDAQ:LUCD
Lucid Diagnostics Inc
EPS (Diluted)
Lucid Diagnostics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
EPS (Diluted)
$6
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
0%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
22%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$7
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$7
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
18%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$6
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
What is Lucid Diagnostics Inc's EPS (Diluted)?
EPS (Diluted)
-1.1
USD
Based on the financial report for Dec 31, 2024, Lucid Diagnostics Inc's EPS (Diluted) amounts to -1.1 USD.
What is Lucid Diagnostics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-54%
Over the last year, the EPS (Diluted) growth was 17%. The average annual EPS (Diluted) growth rates for Lucid Diagnostics Inc have been -9% over the past three years , -54% over the past five years .
You don't have any saved screeners yet